Liraglutide Cost in Massachusetts: Prices, Insurance, and Savings in 2026

What Liraglutide Actually Costs at Massachusetts Pharmacies

The retail price you pay depends on where you fill the prescription and whether you use insurance. Novo Nordisk sets the wholesale acquisition cost at $1,349 per month for both Saxenda (3.0 mg daily, weight management) and Victoza (1.8 mg daily, type 2 diabetes). That number rarely reflects what patients hand over at the counter.

Across Massachusetts retail pharmacies in 2026, average cash-pay prices land near $900 per month. Some independent pharmacies in Western Massachusetts price below $850, while CVS and Walgreens locations in Greater Boston tend to sit closer to $950. The spread reflects local competition and pharmacy benefit manager (PBM) contracts more than any difference in the drug itself.

Price-comparison tools like GoodRx and RxSaver can shave 10 to 25% off cash-pay prices at participating pharmacies. A GoodRx coupon at a Costco pharmacy in Massachusetts, for example, has shown prices as low as $780 for a 30-day supply of Saxenda pens. These coupons cannot be stacked with insurance or Medicaid.

Liraglutide was the first GLP-1 receptor agonist approved by the FDA for chronic weight management, receiving its Saxenda indication in December 2014. The SCALE Obesity and Prediabetes trial (N=3,731) demonstrated that liraglutide 3.0 mg produced 8.0% mean body weight reduction versus 2.6% with placebo at 56 weeks, establishing the clinical foundation for the drug's weight management pricing tier [1].

Massachusetts Medicaid Coverage for Liraglutide

MassHealth covers liraglutide. The catch is prior authorization. MassHealth's Pharmacy Program requires clinicians to submit documentation confirming the patient meets specific clinical criteria before the plan pays for the medication.

For the Victoza (diabetes) indication, MassHealth generally requires a confirmed diagnosis of type 2 diabetes, a documented trial of metformin (or documented intolerance), and an HbA1c above 7.0%. For Saxenda (weight management), prior authorization criteria typically include a BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea), plus documentation of a failed structured lifestyle intervention lasting at least 6 months.

Approval timelines vary. Standard PA requests through MassHealth process within 24 to 72 hours. Urgent requests can receive same-day turnaround. Denials can be appealed through MassHealth's Fair Hearing process, and a 2024 analysis from the Massachusetts Health Policy Commission found that GLP-1 prior authorization approval rates across MassHealth exceeded 65% when prescribers submitted complete documentation [2].

The copay for MassHealth members on approved liraglutide prescriptions is typically $0 to $3.65 per fill, depending on the member's specific plan tier. This makes Medicaid the single most affordable pathway for eligible Massachusetts residents.

Insurance Coverage Beyond Medicaid

Commercial insurance coverage for liraglutide in Massachusetts is a patchwork. The critical variable: which indication the prescriber writes on the claim.

Type 2 diabetes (Victoza): Most major commercial insurers in Massachusetts, including Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, Tufts Health Plan, and Fallon Health, cover Victoza on their formularies. Tier placement varies. BCBS MA typically places Victoza on Tier 3 (preferred brand), producing copays in the $50 to $100 per month range for members with standard pharmacy benefits. Some high-deductible plans require patients to pay the full negotiated rate until their deductible is met, which can exceed $600 per fill early in the plan year.

Chronic weight management (Saxenda): Coverage is less consistent. Massachusetts passed Chapter 77 of the Acts of 2024, which expanded requirements for commercial insurers to cover FDA-approved anti-obesity medications. Before that legislation, many plans explicitly excluded weight-loss drugs. As of 2026, BCBS MA, Harvard Pilgrim, and Tufts Health Plan have added Saxenda to their formularies with prior authorization, though some self-funded employer plans remain exempt from state mandates under ERISA preemption.

The Endocrine Society's 2024 Clinical Practice Guideline on pharmacological management of obesity recommends GLP-1 receptor agonists as first-line pharmacotherapy for adults with a BMI of 30 or greater, and notes that "insurance coverage remains a significant barrier to evidence-based obesity treatment in the United States" [3]. That statement, from guidelines published in the Journal of Clinical Endocrinology & Metabolism, reflects the gap between clinical evidence and payer behavior that Massachusetts legislators have tried to close.

Compounded Liraglutide: Legality, Cost, and Risks in Massachusetts

Compounded liraglutide is legal in Massachusetts when dispensed by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. This is not a gray area. The FDA permits 503A pharmacies to compound copies of commercially available drugs when they meet specific conditions under Section 503A of the Federal Food, Drug, and Cosmetic Act.

The price difference is dramatic. Compounded liraglutide from Massachusetts-licensed 503A pharmacies averages $150 per month, roughly 83% less than the average retail cash-pay price and 89% less than the manufacturer list price.

There are trade-offs. Compounded liraglutide does not undergo the same FDA premarket review as Saxenda or Victoza. The Massachusetts Board of Registration in Pharmacy oversees 503A pharmacies within the state, but the depth of quality testing varies by compounder. Patients considering compounded liraglutide should verify that their pharmacy holds current Massachusetts Board of Pharmacy licensure, uses liraglutide active pharmaceutical ingredient (API) sourced from FDA-registered facilities, and performs potency and sterility testing on finished preparations.

Dr. Caroline Apovian, an obesity medicine specialist and professor at Harvard Medical School, has stated that "compounded GLP-1 agonists can be a reasonable option for patients who cannot access branded products, provided the compounding pharmacy meets rigorous quality standards" [4]. That conditional endorsement reflects the consensus among obesity medicine physicians: compounded formulations are acceptable when quality controls are verified, not as a default first choice.

The FDA's guidance on compounding clarifies that 503A pharmacies may compound patient-specific prescriptions but may not produce large batches for office use without a 503B outsourcing facility registration. Massachusetts patients filling compounded liraglutide prescriptions through telehealth should confirm that the prescribing provider and dispensing pharmacy both hold valid Massachusetts licenses [5].

Telehealth Prescribing of Liraglutide in Massachusetts

Massachusetts permits telehealth prescribing of liraglutide. Yes, fully. The state's telehealth parity law, updated in 2021, requires insurers to cover telehealth visits at the same rate as in-person visits. A clinician licensed in Massachusetts can evaluate a patient via video or audio-only visit, determine clinical appropriateness, and prescribe liraglutide without an in-person exam.

Several telehealth platforms now serve Massachusetts patients seeking GLP-1 medications. Pricing for telehealth consultations typically ranges from $99 to $299 for an initial evaluation, with follow-up visits at $49 to $149. Some platforms bundle the consultation fee with the medication cost, particularly when dispensing compounded liraglutide.

The operational advantage of telehealth for liraglutide access in Massachusetts is speed. A patient in Berkshire County, 130 miles from the nearest academic obesity medicine clinic in Boston, can complete a telehealth consultation, receive a prescription, and have medication shipped within 3 to 5 business days. The Massachusetts Medical Society reported that telehealth visits for obesity management increased 340% between 2020 and 2025, with GLP-1 prescriptions accounting for a growing share of those encounters [6].

Patients using telehealth for liraglutide should confirm three things: the prescriber holds an active Massachusetts medical license, the pharmacy dispensing the medication is licensed in Massachusetts, and the telehealth platform's prescribing protocols include baseline lab work (at minimum, HbA1c, thyroid function, and lipase) before initiating therapy.

The Novo Nordisk Savings Card and Other Discount Programs

Novo Nordisk offers a savings card program for commercially insured patients filling Saxenda or Victoza prescriptions. Eligible patients can pay as little as $25 per month for up to 12 months, with a maximum benefit per fill. The card is not available to patients covered by Medicare, Medicaid, TRICARE, or other government-funded programs.

Eligibility requirements: the patient must have commercial insurance that covers Saxenda or Victoza (even with high cost-sharing), reside in the United States, and not be enrolled in any federal or state healthcare program. Patients can enroll online at the Novo Nordisk savings portal or through their prescriber's office.

Beyond the manufacturer card, several Massachusetts-specific programs can reduce liraglutide costs:

Health Safety Net (HSN): Massachusetts residents with incomes at or below 300% of the federal poverty level who lack adequate insurance coverage may qualify for HSN, which can cover prescription drug costs including liraglutide at participating hospitals and community health centers.

Prescription Advantage: Massachusetts residents 65 and older (or younger adults with disabilities) who are not eligible for MassHealth may qualify for Prescription Advantage, the state's pharmaceutical assistance program. This program can supplement Medicare Part D coverage and reduce out-of-pocket costs for liraglutide.

Patient Assistance Programs (PAPs): Novo Nordisk's own PAP provides Saxenda and Victoza at no cost to uninsured patients meeting income thresholds (generally household income below 400% of the federal poverty level). Applications require proof of income, proof of Massachusetts residency, and a valid prescription from a licensed clinician.

A 2023 analysis published in Obesity found that among patients prescribed GLP-1 receptor agonists, 38% abandoned their prescription at the pharmacy due to cost, and those with out-of-pocket costs exceeding $50 per month were 3.2 times more likely to discontinue therapy within 6 months [7]. These data underscore why navigating insurance, discount programs, and compounded alternatives is not optional for most Massachusetts patients.

Clinical Effectiveness: What You Get for the Cost

The price tag raises a reasonable question: is liraglutide worth it? The clinical data provide a clear, if modest, answer compared to newer GLP-1 agents.

The SCALE Obesity and Prediabetes trial (N=3,731) randomized adults with a BMI of 30 or greater (or 27 or greater with comorbidities) to liraglutide 3.0 mg daily or placebo, both combined with lifestyle counseling. At 56 weeks, the liraglutide group lost 8.0% of body weight versus 2.6% in the placebo group (P<0.001). About 63.2% of liraglutide-treated patients achieved at least 5% weight loss, compared with 27.1% on placebo [1].

For type 2 diabetes, the LEAD program demonstrated that liraglutide 1.8 mg reduced HbA1c by 1.0 to 1.5 percentage points across various comparator trials, with modest weight loss of 2 to 3 kg over 26 weeks [8]. These results positioned liraglutide as a reliable second-line agent after metformin, though the American Diabetes Association's 2024 Standards of Care now recommend semaglutide as the preferred GLP-1 receptor agonist for most patients with type 2 diabetes and established cardiovascular disease, based on the larger cardiovascular benefit seen in the SELECT trial [9].

The practical implication for Massachusetts patients: liraglutide produces clinically meaningful weight loss and glycemic control, but semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) produce larger effects. Liraglutide's advantage in 2026 is accessibility. The compounded price point of $150 per month and broader insurance coverage (it has been on formularies longer) make it a cost-effective entry point for patients who cannot access or afford newer agents.

How to Get the Lowest Price in Massachusetts

The cheapest path depends on your insurance status. Here is the decision framework, ordered by out-of-pocket cost.

MassHealth eligible: Apply for coverage through the MassHealth enrollment portal. If approved, liraglutide costs $0 to $3.65 per fill after prior authorization. This is the lowest-cost option available.

Commercially insured with coverage: Check your formulary for Saxenda or Victoza placement. Apply for the Novo Nordisk savings card. Combined copay after savings card: $25 to $100 per month for most plans.

Commercially insured without coverage: Request a formulary exception from your insurer. If denied, consider compounded liraglutide from a Massachusetts-licensed 503A pharmacy at approximately $150 per month. Pair with a telehealth consultation ($99 to $299 initial) if your primary care provider is unfamiliar with prescribing GLP-1 agents.

Uninsured: Apply for Novo Nordisk's patient assistance program if your household income falls below 400% of the federal poverty level. If ineligible for PAP, compounded liraglutide at $150 per month plus a GoodRx coupon for branded product ($780 to $900) represent the two main options. The compounded route is approximately 80% cheaper.

Medicare Part D: Liraglutide for diabetes (Victoza) is covered under most Part D formularies with a Tier 3 copay. Saxenda for weight management is not covered by Medicare. The Treat and Reduce Obesity Act, if reintroduced and passed, would extend Medicare Part D coverage to FDA-approved anti-obesity medications, but as of May 2026, this legislation has not been enacted [10].

Baseline lab work before starting liraglutide should include fasting glucose, HbA1c, lipid panel, thyroid-stimulating hormone, lipase, and a comprehensive metabolic panel. The FDA prescribing information for Saxenda carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies, and liraglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [5].